

Dear Stockholders,

After almost ten years on the Supervisory Board of LANXESS, including six years as Chairman, I have decided not to stand for reelection at this year's Annual Stockholder's Meeting. For me, this marks the end of an exciting journey in the company and I would like to take this as an opportunity to thank you for your trust and support.

During my time at LANXESS, our portfolio underwent a profound transformation from a high-volume synthetic rubber supplier to a specialty chemicals company with a focus on consumer-oriented products.

The gradual exit from the rubber business in 2016 and the acquisition of the listed US specialty additives company Chemtura in 2017 were followed by key milestones in the group's transformation with significant acquisitions in the USA of Emerald Kalama Chemical in 2021 and the Microbial Control business from IFF in 2022.

LANXESS sold non-strategic businesses such as the remaining joint venture interest in ARLANXEO to Saudi Aramco in 2018. In 2023, the High Performance Materials business was contributed to the Envalior joint venture with Advent. With its approximately 40% stake, LANXESS retains the opportunity to benefit from growth and synergies through a later sale.

It has always been essential to allocate the proceeds from disposals in the best interests of our shareholders. In addition to financing the aforementioned acquisitions and reducing debt, the proceeds from the sale of our stake in the Chempark operator CURRENTA in 2020 were also used to buy back our own shares.

During the strategic realignment, LANXESS has continuously met the target of a consistent investment grade rating and the payment of a dividend in every financial year - even in the past difficult years.

April 16, 2024

LANXESS AG

Investor Relations 50569 Cologne Germany

Phone: +49 221 8885 1272 Fax: +49 221 8885 4944

Page 1 of 3



I am particularly proud of our success in the areas of sustainability and climate protection. Back in 2019, we were one of the first major chemical companies to announce that we would become climate-neutral by 2040 and reduce our greenhouse gas emissions (Scope 1+2). We extended this target in 2023 to include emissions from upstream and downstream supply chains (Scope 3). We would also like to make these supply chains climate-neutral by 2050.

With regard to my succession I am very pleased that Dr. Rainier van Roessel is available to take over as Chairman of the Supervisory Board and is standing for election to the Supervisory Board for this position. When filling vacant supervisory board positions, we always put our focus on the right balance of personal skills, experience and professional expertise. As we are currently facing exceptionally difficult and to some extent unprecedented times for the global economy in general and the chemical industry in particular, personnel continuity and an in-depth knowledge of the specifics of the chemical industry are our top priorities when it comes to succession planning for key corporate positions. For these reasons, Dr. van Roessel fits perfectly into our qualification profile of the Supervisory Board chair of LANXESS. Thanks to his industry experience of more than 35 years starting his career at Bayer and accompanying LANXESS from day one of the company - he not only has tremendous industry expertise, but also a unique understanding of the company's processes, stakeholders, relevant customers and product markets. In addition, as former longstanding Director of Labor Relationships, he has proven communication skills that provide an excellent basis to ensure a balance of interests between the shareholders and employee representatives on the Supervisory Board, even in a challenging environment.

I am confident that the Board of Management and the Supervisory Board, chaired by Dr. van Roessel, will consistently continue on the chosen path and lead LANXESS to further growth and success in the coming years. I personally wish him all the best and every success in his future endeavors.

LANXESS AG

Investor Relations 50569 Cologne Germany

Phone: +49 221 8885 1272 Fax: +49 221 8885 4944

Page 2 of 3



Dear shareholders, I look back on my time at LANXESS with gratitude and confidence. The company is well positioned to master current and future challenges. I would like to thank you all for your continued trust and support which has enabled us to make LANXESS what it is today.

Best regards

LANXESS AG

Investor Relations 50569 Cologne Germany

Phone: +49 221 8885 1272 Fax: +49 221 8885 4944

Page 3 of 3

Dr. Matthias L. Wolfgruber